1.28
price up icon3.23%   0.04
after-market アフターアワーズ: 1.27 -0.01 -0.78%
loading
前日終値:
$1.24
開ける:
$1.22
24時間の取引高:
10,519
Relative Volume:
0.03
時価総額:
$34.46M
収益:
$9.06M
当期純損益:
$-50.39M
株価収益率:
-0.6667
EPS:
-1.92
ネットキャッシュフロー:
$5.89M
1週間 パフォーマンス:
-2.29%
1か月 パフォーマンス:
+0.79%
6か月 パフォーマンス:
-32.63%
1年 パフォーマンス:
-58.71%
1日の値動き範囲:
Value
$1.22
$1.28
1週間の範囲:
Value
$1.20
$1.33
52週間の値動き範囲:
Value
$0.8502
$3.20

Lava Therapeutics Nv Stock (LVTX) Company Profile

Name
名前
Lava Therapeutics Nv
Name
セクター
Healthcare (1152)
Name
電話
31 6 3000 3035
Name
住所
YALELAAN 62, UTRECHT
Name
職員
34
Name
Twitter
Name
次回の収益日
2025-03-28
Name
最新のSEC提出書
Name
LVTX's Discussions on Twitter

LVTX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
LVTX
Lava Therapeutics Nv
1.28 34.46M 9.06M -50.39M 5.89M -1.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
501.15 126.96B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.61 65.06B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
649.67 37.54B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
259.39 32.56B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
255.77 26.40B 3.81B -644.79M -669.77M -6.24

Lava Therapeutics Nv Stock (LVTX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-12 ダウングレード Leerink Partners Outperform → Market Perform
2024-12-11 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2022-10-25 開始されました H.C. Wainwright Buy
2021-04-19 開始されました JP Morgan Overweight
2021-04-19 開始されました Jefferies Buy
2021-04-19 開始されました SVB Leerink Outperform
すべてを表示

Lava Therapeutics Nv (LVTX) 最新ニュース

pulisher
Apr 16, 2025

LAVA Therapeutics Strengthens Balance Sheet with $5.1 Million Repayment Waiver from Netherlands Enterprise Agency - Nasdaq

Apr 16, 2025
pulisher
Apr 16, 2025

Lava Therapeutics Granted Full Waiver For RVO Payment Obligation - marketscreener.com

Apr 16, 2025
pulisher
Apr 16, 2025

LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation - GlobeNewswire

Apr 16, 2025
pulisher
Apr 16, 2025

LAVA Therapeutics Strengthens Balance Sheet: Secures Complete Waiver of $5.1M Debt - Stock Titan

Apr 16, 2025
pulisher
Apr 06, 2025

Investors Aren't Buying LAVA Therapeutics N.V.'s (NASDAQ:LVTX) Revenues - simplywall.st

Apr 06, 2025
pulisher
Apr 01, 2025

Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads after asset cut - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

LAVA Therapeutics (NASDAQ:LVTX) Receives Neutral Rating from HC Wainwright - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

Leerink cuts Lava Therapeutics stock target to $1 By Investing.com - Investing.com Canada

Mar 31, 2025
pulisher
Mar 31, 2025

Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads after asset cut By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Leerink cuts Lava Therapeutics stock target to $1 - Investing.com

Mar 31, 2025
pulisher
Mar 31, 2025

JMP maintains LAVA Therapeutics stock Market Perform rating By Investing.com - Investing.com Australia

Mar 31, 2025
pulisher
Mar 31, 2025

JMP maintains LAVA Therapeutics stock Market Perform rating - Investing.com

Mar 31, 2025
pulisher
Mar 28, 2025

Lava Therapeutics Reports 2024 Financial Results - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

LAVA Therapeutics NV earnings beat by $0.16, revenue topped estimates - Investing.com Australia

Mar 28, 2025
pulisher
Mar 28, 2025

LAVA Therapeutics N.V. (LVTX) reports earnings - Quartz

Mar 28, 2025
pulisher
Mar 28, 2025

LAVA Therapeutics NV SEC 10-K Report - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

LAVA Therapeutics NV reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - GlobeNewswire

Mar 28, 2025
pulisher
Mar 28, 2025

LAVA Therapeutics Q4 Basic EPS USD -0.14 - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

LAVA Therapeutics Slashes Workforce 30% While Securing $12M in Big Pharma Milestone Payments - Stock Titan

Mar 28, 2025
pulisher
Mar 12, 2025

Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads amid pipeline shifts By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 12, 2025

Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads amid pipeline shifts - Investing.com

Mar 12, 2025
pulisher
Feb 28, 2025

Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang - Benzinga

Feb 28, 2025
pulisher
Feb 27, 2025

This Constellation Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Benzinga

Feb 27, 2025
pulisher
Feb 25, 2025

LAVA Therapeutics Reviews Strategic Alternatives, Announces 30% Staff Cut - Nasdaq

Feb 25, 2025
pulisher
Feb 25, 2025

LAVA Therapeutics Announces Restructuring Plan for 2025 - TipRanks

Feb 25, 2025
pulisher
Feb 25, 2025

LAVA Announces Evaluation of Strategic Options - GlobeNewswire

Feb 25, 2025
pulisher
Feb 25, 2025

Can LAVA Therapeutics Find a Buyer? Company Cuts 30% of Staff While Exploring Strategic Options - StockTitan

Feb 25, 2025
pulisher
Feb 13, 2025

LVTX stock touches 52-week low at $0.88 amid market challenges - Investing.com Australia

Feb 13, 2025
pulisher
Feb 12, 2025

LVTX stock touches 52-week low at $0.88 amid market challenges By Investing.com - Investing.com South Africa

Feb 12, 2025
pulisher
Feb 06, 2025

LAVA Therapeutics (NASDAQ:LVTX) Stock Price Down 4.6% – Here’s What Happened - Defense World

Feb 06, 2025
pulisher
Jan 27, 2025

RNA Editing Market Top Companies StudyQIAGEN N.V., UniquQuire - openPR

Jan 27, 2025
pulisher
Jan 10, 2025

LAVA Therapeutics begins trial for cancer treatment - Investing.com India

Jan 10, 2025
pulisher
Jan 10, 2025

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers - GlobeNewswire

Jan 10, 2025
pulisher
Jan 10, 2025

LAVA Therapeutics Initiates Phase 1 Trial for Novel Leukemia Treatment LAVA-1266 - StockTitan

Jan 10, 2025
pulisher
Jan 09, 2025

LAVA Therapeutics NV (LVTX)’S -5.56% Retreat Makes It Worth Considering Again - Stocks Register

Jan 09, 2025
pulisher
Jan 04, 2025

LAVA Therapeutics NV Files 8-K with SEC, Transitioning to U.S. Domestic Issuer Status - Defense World

Jan 04, 2025
pulisher
Dec 26, 2024

LVTX stock touches 52-week low at $0.95 amid market challenges - Investing.com

Dec 26, 2024
pulisher
Dec 20, 2024

H.C. Wainwright maintains Buy on Lava Therapeutics shares despite pipeline reprioritization By Investing.com - Investing.com South Africa

Dec 20, 2024
pulisher
Dec 20, 2024

H.C. Wainwright maintains Buy on Lava Therapeutics shares despite pipeline reprioritization - Investing.com

Dec 20, 2024
pulisher
Dec 18, 2024

LAVA Therapeutics stock hits 52-week low at $0.98 - Investing.com

Dec 18, 2024

Lava Therapeutics Nv (LVTX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$72.30
price down icon 0.47%
$21.48
price up icon 2.63%
$32.89
price up icon 1.26%
$27.90
price up icon 13.09%
$104.94
price up icon 2.45%
biotechnology ONC
$255.77
price up icon 0.05%
大文字化:     |  ボリューム (24 時間):